Navigation Links
NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
Date:4/15/2009

on of Pediatric Infectious Diseases; and Vice- Chairman, Department of Pediatrics. Dr. Whitley has served on several editorial and advisory boards and is currently the Vice President and President Elect for the Infectious Disease Society of America. Since 1980 Dr. Whitley has served as the Project Director for NIAID's Collaborative Antiviral Study Group, a multi-center clinical trial network directed to conduct studies to evaluate novel antiviral therapies that target unmet medical needs.

    More information on each CAB member may be found on the company's web site.


    ABOUT NEXBIO

NexBio, Inc. is a privately held development-stage biopharmaceutical company located in San Diego. NexBio's mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases. DAS181 (Fludase(R)), a recombinant fusion protein, inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza, including potential pandemic strains, and parainfluenza viruses (which may cause serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic) from infecting the human body or from amplifying in infected individuals. Unlike current antiviral compounds and vaccines, DAS181 targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with the currently available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance. Furthermore, DAS181 has been shown effective against influenza that is resistant to Tamiflu(R). The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Viradin(TM), invented and developed by NexBio, is a
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NexBio to Present at 2009 Biotech Showcase
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
4. Gen-Probe Completes Acquisition of Tepnel Life Sciences
5. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
6. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
7. Atritech Completes $30 Million Financing
8. Roche Completes Tender Offer for Genentech
9. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
10. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
11. Sangart, Inc. Completes Series F Funding Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 1000 balances – 4 ... on customers’ weighing needs and expertly narrows down the ... balances, scales or even terminals. , First, select ... weight (or select readability instead) and define the accuracy ... selection criteria narrows down the list to models that ...
(Date:7/24/2014)... Draper University, a top program ... announce that for 6 weeks this summer, 39 ... on the Draper University campus in the heart ... focused on entrepreneurship, building real-world skills, and “learning ... its sixth cohort, continues to refresh its curriculum ...
(Date:7/24/2014)... July 24, 2014   Cypher Genomics, Inc., ... appointment of Adam Simpson as president ... rapid and comprehensive annotation and interpretation of individual ... "Cypher,s technology has the potential to ... enhancing diagnostic accuracy, optimizing therapeutic approaches and reducing ...
(Date:7/24/2014)... San Diego, CA (PRWEB) July 24, 2014 ... in the reporting of molecular diagnostic test results. ... tracking capabilities necessary for the validation and reporting ... in oncology. Molecular diagnostics is a rapidly growing ... for infectious disease, genetic predisposition, cancer, and companion ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2
... , , , , ... Primer anneal. temp. , Sensitivity , Specifi- , ... Tolerance , of non- , specific RNA , ... of serum components , Carry-over , prevention ...
... amplification of up to 3 kb genomic , DNA targets Cat. No. 1 647 679 ... 647 687 4 x 250 units (1 unit/l) , Cat. No. 1 146 165 100 ... Cat. No. 1 418 432 4 x 250 units (5 units/l) , ... 1 435 094 20 x 250 units (5 units/l) , , , , ...
... , Explore New Horizons in Amplification Yield, , ... High Yield, Accuracy, and the Prevention , of Carry-Over Contamination ... Roche Applied Science, which pioneered the blending , ... Long Template PCR Systems, now introduces the Expand High FidelityPLUS PCR , ...
Cached Biology Technology:Reverse transcriptases suitable for one-step RT-PCRb 2Taq DNA Polymerase 2Taq DNA Polymerase 3Expand High FidelityPLUS PCR System 2Expand High FidelityPLUS PCR System 3
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... provide much higher yield than their homozygous parents. Plant ... and used this effect called heterosis for richer harvests. ... underlying this phenomenon. Researchers at the University of Bonn ... decoded one possible mechanism in corn roots. More genes ...
... are known to be prodigious jumpers on land. Now, researchers ... , a Cell Press publication, have found that the tiny ... water, too. Their secret is a series of spring-loaded, oar-like ... have solved the most difficult task of jumping from the ...
... Grumman Corporation (NYSE: NOC ) has successfully ... biometric information system (ABIS) for the Australian Department of ... period to enable testing and refinement of analytical techniques ... the requirements for a future biometrics information management solution. ...
Cached Biology News:Corn: Many active genes - high yield 2Corn: Many active genes - high yield 3Pygmy mole crickets don't just walk on water, they jump on it 2Northrop Grumman Delivers Australian Automated Biometric Information System Trial Proof of Concept 2
Tube-O-DIALYZER Floats, small....
Feline Rhinotracheitis Virus...
Ezrin/Radixin/Moesin Antibody...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: